Coronary Artery Calcification in Individuals with CKD: Slowing the Progression (Supported by an Educational Grant from Sanofi Renal)

Contact hours available until 4/24/2015

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Faculty, Planners and Authors Conflict of Interest Disclosure:
Planning Committee:
Kristin Larson – Consultant, Nephrology Clinical Solutions; Employee, Affymax; Other financial support, Kristin M. Larson, RN, MSN, LLC; Sandy Bodin – Employee, Affymax; Dawn Koonkongsatian – Employee, Fresenius Medical Care; Elizabeth St. John - Employee, Fresenius Medical Care

Presenter(s) have no disclosures to declare.

Commercial Support and Sponsorship:
Supported by an unrestricted educational grant from Sanofi Renal.

Non-Endorsement of Products:
Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by ANNA or the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:
• Discuss the pathophysiology that occurs when a positive calcium balance is noted in an individual with CKD or in
  incident dialysis patients.
• Describe the impact of coronary artery calcification on the normal individual and those with stage 3 or later CKD.
• Analyze the impact of patient risk factors and laboratory values on the development of MBD.
• Recognize effective treatment strategies to minimize CAC in the individual with CKD or incident to hemodialysis."